NYSE:AGEAgeX Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AgeX Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.89 +0.02 (+2.30 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.86Now: $0.89▼$0.9350-Day Range$0.71MA: $0.86▼$1.1352-Week Range$0.67Now: $0.89▼$3.38Volume148,420 shsAverage Volume392,389 shsMarket Capitalization$33.48 millionP/E RatioN/ADividend YieldN/ABeta2.3 ProfileAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues. It is also involved in the development of AGEX-iTR1547, a drug-based formulation in preclinical development for restoring regenerative potential in various aged tissues afflicted with degenerative diseases. In addition, the company develops Renelon, a first-generation tissue regeneration product designed to promote scarless tissue repair. Further, it markets genomic interpretation algorithms; and Cytiva, including pluripotent stem cell derived heart muscle cells used in screening drugs for efficacy and safety. The company was founded in 2017 and is based in Alameda, California. AgeX Therapeutics, Inc.(AMEX:AGE) operates independently of BioTime, Inc. as of November 28, 2018.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for AgeX Therapeutics. Previous Next 2.4 Community Rank Outperform VotesAgeX Therapeutics has received 49 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAgeX Therapeutics has received 55 “underperform” votes. (Add your “underperform” vote.)Community SentimentAgeX Therapeutics has received 52.88% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AgeX Therapeutics and other stocks. Vote “Outperform” if you believe AGE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAgeX Therapeutics does not currently pay a dividend.Dividend GrowthAgeX Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AgeX Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.10% of the stock of AgeX Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.87% of the stock of AgeX Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of AgeX Therapeutics is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AgeX Therapeutics is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgeX Therapeutics has a P/B Ratio of 12.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:AGE Previous Symbol CUSIPN/A CIKN/A Webwww.agexinc.com Phone510-671-8370Debt Debt-to-Equity RatioN/A Current Ratio0.38 Quick Ratio0.38Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.73 million Price / Sales19.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book12.70Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-12,150,000.00 Net Margins-658.11% Return on Equity-334.65% Return on Assets-157.65%Miscellaneous EmployeesN/A Outstanding Shares37,660,000Market Cap$33.48 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable AGE Rates by TradingView Receive AGE News and Ratings via Email Sign-up to receive the latest news and ratings for AGE and its competitors with MarketBeat's FREE daily newsletter. AgeX Therapeutics (NYSE:AGE) Frequently Asked Questions How has AgeX Therapeutics' stock been impacted by COVID-19 (Coronavirus)? AgeX Therapeutics' stock was trading at $0.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AGE stock has increased by 1.0% and is now trading at $0.8891. View which stocks have been most impacted by Coronavirus. When is AgeX Therapeutics' next earnings date? AgeX Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for AgeX Therapeutics. How were AgeX Therapeutics' earnings last quarter? AgeX Therapeutics (NYSE:AGE) issued its earnings results on Thursday, May, 14th. The company reported ($0.08) EPS for the quarter. The company had revenue of $0.52 million for the quarter. AgeX Therapeutics had a negative return on equity of 334.65% and a negative net margin of 658.11%. View AgeX Therapeutics' earnings history. Has AgeX Therapeutics been receiving favorable news coverage? Media stories about AGE stock have trended negative on Monday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AgeX Therapeutics earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about AgeX Therapeutics. Who are some of AgeX Therapeutics' key competitors? Some companies that are related to AgeX Therapeutics include Rockwell Medical (RMTI), Mustang Bio (MBIO), Arbutus Biopharma (ABUS), ESSA Pharma (EPIX), PhaseBio Pharmaceuticals (PHAS), Aldeyra Therapeutics (ALDX), Sierra Oncology (SRRA), Inflarx (IFRX), Bellerophon Therapeutics (BLPH), Catabasis Pharmaceuticals (CATB), Conatus Pharmaceuticals (CNAT), Theratechnologies (THERF), Genprex (GNPX), OASMIA PHARMACE/ADR (OASM) and Leap Therapeutics (LPTX). View all competitors. What other stocks do shareholders of AgeX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AgeX Therapeutics investors own include Energy Transfer LP Unit (ET), AT&T (T), Allena Pharmaceuticals (ALNA), Huntington Bancshares (HBAN), Lineage Cell Therapeutics (LCTX), Main Street Capital (MAIN), Omega Healthcare Investors (OHI), Viking Therapeutics (VKTX), Washington Prime Group (WPG) and AbbVie (ABBV). Who are AgeX Therapeutics' key executives? AgeX Therapeutics' management team includes the following people: Mr. Alfred D. Kingsley, Exec. Chairman (Age 75)Dr. Michael D. West, Pres, CEO & Director (Age 65)Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)Mr. Nafees Naseer Malik, Chief Operating OfficerDr. Aubrey D. N. J. de Grey BA, MA,Ph.D., Vice-Pres of New Technology Discovery What is AgeX Therapeutics' stock symbol? AgeX Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGE." How do I buy shares of AgeX Therapeutics? Shares of AGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AgeX Therapeutics' stock price today? One share of AGE stock can currently be purchased for approximately $0.89. How big of a company is AgeX Therapeutics? AgeX Therapeutics has a market capitalization of $33.48 million and generates $1.73 million in revenue each year. What is AgeX Therapeutics' official website? The official website for AgeX Therapeutics is www.agexinc.com. How can I contact AgeX Therapeutics? AgeX Therapeutics' mailing address is 965 ATLANTIC AVENUE SUITE 101, ALAMEDA CA, 94501. The company can be reached via phone at 510-671-8370. This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
